Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrimson Tide Regulatory News (TIDE)

Share Price Information for Crimson Tide (TIDE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 162.50
Bid: 155.00
Ask: 170.00
Change: 0.00 (0.00%)
Spread: 15.00 (9.677%)
Open: 162.50
High: 162.50
Low: 162.50
Prev. Close: 162.50
TIDE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Win

7 Jun 2012 07:00

RNS Number : 8451E
Crimson Tide PLC
07 June 2012
 

PRESS RELEASE

7 June 2012

Crimson Tide PLC

("Crimson Tide" or "the Company")

CRIMSON TIDE WINS CONTRACT WITH TCP HOMECARE TO INSTALLMPRO APP IN EVERY HOSPITAL TREATING HAEMOPHILIA IN IRELAND

Number of haemophilia patients using system at home to increase with additional contract

Crimson Tide - a leading provider of customised business Smartphone applications (mpro) has won a contract with TCP Homecare for a unique mpro hospital application, which will ensure that medication infusions performed on patients suffering from the genetic disease, haemophilia, are carried out in hospital at the maximum level of safety possible.

In Ireland alone there are 2,300 patients living with Haemophilia. It is a requirement for every hospital to hold a stock of life-saving medication in the event that a patient, living or visiting in the local vicinity, needs an infusion due to a medical emergency. If such a case arises, the mpro application will guide the care provider through vital safety checks that need to be carried out before medication-administration is performed. This is made possible through the integration of the industry standard GS1 track-and-trace barcode system. Every patient, medication vial box and location in the supply chain is assigned a globally unique identifier, which in most cases is in the form of a 2D barcode.

The mpro application instructs the care provider to check that the patient's details match those stored in TCP's patient database, which is populated by the Electronic Patient Record (EPR) situated in St. James' Hospital, Dublin. Via use of the barcode scanner on a PDA, the care provider is instructed by the mpro application to scan the medication vial box, which checks that the medication matches the patient's prescription as stored on the database, that it is in date and that it is not on a recall list. Where it is safe to issue the medication, the user is prompted to enter the reason for infusion - ultimately forming part of the treatment history in the patient's electronic chart.

All communication between the TCP database and PDA is managed via Private APN - ensuring that maximum security is maintained. Furthermore, the mpro application will also be able to record any product returns in addition to performing monthly stock takes.

The initial rollout of the mpro hospital application is about to commence at hospitals in Crumlin and St Vincent's, prior to the system being implemented at all 33 hospitals and health centres in Ireland. A similar mpro application is already in use in Ireland by individuals suffering from severe Haemophilia who need to self-medicate in their own homes. These individuals have reported a highly positive response to the PDA application and the number of users is increasing to 125 patients. It fills these individuals with a great sense of relief to know that their medication is completely safe for them to use and that their condition is being closely monitored. In July this year the company will also present its Haemophilia application at the World Federation of Haemophilia in Paris.

"Our collaboration with TCP will further improve the clinical management of haemophilia in Ireland. By relieving hospital staff from excess paperwork, the mpro application will reduce the risk of human error and losing paperwork, while allowing staff to devote more time to patient care. Implementing protocols that regulate safe administration of medications to patients is not only vital in the case of haemophilia, but highly applicable for many other disease groups", says Barrie Whipp, Crimson Tide's Executive Chairman. 

- ends -

For further information:

Crimson Tide plc

Barrie Whipp, Executive Chairman

01892 542 444

WH Ireland

James Joyce

 

020 7220 1666

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUGURGQUPPGQQ
Date   Source Headline
30th Sep 200511:41 amRNSInterim Results
30th Jun 20055:25 pmRNSFinal Results
21st Feb 200511:11 amRNSRule 8 - Cohen(A.) & Co PLC
21st Feb 200510:52 amRNSBoard Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.